Skip to main content

Advertisement

SpringerLink
Log in

Protective effect of amifostine against cisplatin-induced motor neuropathy in rat

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cisplatin (CDDP) is a potent anticancer drug. Neurotoxicity is one of the most important dose-limiting toxicity of CDDP. We investigated the role of amifostine in the protection against CDDP-induced neurotoxicity especially on the motor nerves. All experiments were conducted on female Wistar albino rats. Animals were randomly assigned to two groups, each including six rats. Group A received CDDP plus amifostine and Group B received CDDP only. Electroneurography (ENG) was carried out in the beginning and at the end of 7 wk; then, the rats were sacrificed and the sciatic nerve was removed for histopathological examination.

The mean initial latency was 2.4667 msn for group A and 2.44833 msn for group B. After 7 wk of treatment, the latency was 2.9167 for group A and 2.6333 for group B. The difference in latencies was not statistically significant. The amplitude was 11.7853 mV and 13.533 mV for groups A and B, respectively. After 7 wk of treatment, the amplitude was 9.400 mV and 9.000 mV, respectively. The decrease of amplitude in compound muscle action potential (CMAP) was 20% in the amifostine group and the decrease was 33% in the untreated group. The mean area of the CMAP in group A was 9.400 mVsn initially and 9.666 mVsn at the end of the treatment; there was a 0.3% increase despite CDDP treatment. In group B, the mean area of the CMAP was 13.816 mVsn initially and 11.857 mVsn at the end of the treatment; this corresponded to a statistically significant 14% decrease as a result of CDDP treatment. The ENG and histopathological studies showed that at the given dose and schedule CDDP-induced motor neuropathy and amifostine reduced this neuropathy both by protection of the amplitude and area of the CMAP in ENG studies and by sparing a larger number of nerve fibers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anand, A.J. and Bashey, B. (1993). New insights into cisplatin nephrotoxicity. Ann. Pharmacother. 27:1519–1525.

    PubMed  CAS  Google Scholar 

  2. Orhan, B., et al. (1998). Does cisplatin stimulate erythropoietin secretion from the peritubuler cells of the kidney? Clin. Nephrol. 50:202–203.

    PubMed  CAS  Google Scholar 

  3. Aggarwal, S.K. (1993). A histochemical approach to the mechanism of action of cisplatin and its analogs. J. Histochem. Cytochem. 41:1053–1073.

    PubMed  CAS  Google Scholar 

  4. Hamers, F.P., et al. (1993). Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 53:544–549.

    PubMed  CAS  Google Scholar 

  5. Tredici, G., et al. (1994). Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology 15:701–704.

    PubMed  CAS  Google Scholar 

  6. Cavaletti, G., Minoia, C., Schieppati, M. and Tredici, G. (1994). Protective effect of glutathione on cisplatin neurotoxicity in rats. Int. J. Radiat. Oncol. Biol. Phys. 29:771–776.

    PubMed  CAS  Google Scholar 

  7. Cece, R., et al. (1995). An ultrastructural study of neuronal changes in dorsal root ganglia (DGR) of rats after chronic cisplatin administrations. Histol. Histopathol. 10:837–845.

    PubMed  CAS  Google Scholar 

  8. Tredici, G., et al. (1999). Effect of recombinant nerve growth factor on cisplatin neurotoxicity in rats. Exp. Neurol. 159:551–558.

    Article  PubMed  CAS  Google Scholar 

  9. DeKoning, P., Neijt, J.P., Jennekens, F.G. and Gispen, W.H. (1987). Evaluation of cis-diamminedichloroplatinum II (cisplatin) neurotoxicity in rats. Toxicol. Appl. Pharmacol. 89:81–87.

    Article  CAS  Google Scholar 

  10. Yang, Q., et al. (2000). Effect of maturation on nerve excitability in an experimental model of threshold electrotonus. Muscle Nerve 23:498–506.

    Article  PubMed  Google Scholar 

  11. Caveletti, G., et al. (1992). Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. (Berl.) 84:364–371.

    Google Scholar 

  12. Yalcin, S., et al. (1996). Granulocyte-colony stimulating factor (G-CSF) administration for chemotherapy-induced neutropenia. Hematology 1:155–162.

    CAS  Google Scholar 

  13. Yalcin, S. and Orhan, B. (1998). Recombinant human erythropoietin in the treatment of chronic anemia of cancer. Acta Haematol. 100:1152.

    Google Scholar 

  14. Yalcin, S., Güllü, I., Demiroglu, H. and Tekuzman, G. (1997). Acute leukemia during tamoxifen therapy. Med. Oncol. 14:61–62.

    Article  PubMed  CAS  Google Scholar 

  15. Yalcin, S., et al. (1999). Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic single-day chemotherapy: a randomized study. Am. J. Clin. Oncol. 22:94–96.

    Article  PubMed  CAS  Google Scholar 

  16. Spencer, C.M. and Goa, K.L. (1995). Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 50:1001–1031.

    PubMed  CAS  Google Scholar 

  17. Santini, V. and Giles, F.J. (1999). The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica 84:1035–1042.

    PubMed  CAS  Google Scholar 

  18. Foster-Nora, J.A. and Siden, R. (1997). Amifostine for protection from antineoplastic drug toxicity. Am. J. Health-Syst Pharm. 54:787–800.

    PubMed  CAS  Google Scholar 

  19. Tannehill, S.P. and Mehta, M.P. (1996). Amifostine and radiation therapy: past, present, and future. Semin. Oncol. 23(Suppl. 8):69–77.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Oncology, Hacettepe University, Ankara, Turkey

    Suayib Yalcin

  2. Department of Neurology, Hacettepe University, Ankara, Turkey

    Gulay Nurlu

  3. Department of Histology and Embryology, Hacettepe University, Ankara, Turkey

    Dilara Zeybek & Sevda Müftüoğlu

  4. Department of Internal Medicine, Hacettepe University, Ankara, Turkey

    Banu Şarer

  5. Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Berna Akkuş Yildirim & Eren Cetin

  6. Ali Osman Sönmez Oncology Hospital, Bursa, Turkey

    Bülent Orhan

Authors
  1. Suayib Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gulay Nurlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bülent Orhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dilara Zeybek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sevda Müftüoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Banu Şarer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Berna Akkuş Yildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eren Cetin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suayib Yalcin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yalcin, S., Nurlu, G., Orhan, B. et al. Protective effect of amifostine against cisplatin-induced motor neuropathy in rat. Med Oncol 20, 175–180 (2003). https://doi.org/10.1385/MO:20:2:175

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:20:2:175

Key Words

Search

Navigation